MX2012002531A - Generacion de una respuesta amplia de celulas t en humanos contra el virus de inmunodeficiencia humana (vih). - Google Patents
Generacion de una respuesta amplia de celulas t en humanos contra el virus de inmunodeficiencia humana (vih).Info
- Publication number
- MX2012002531A MX2012002531A MX2012002531A MX2012002531A MX2012002531A MX 2012002531 A MX2012002531 A MX 2012002531A MX 2012002531 A MX2012002531 A MX 2012002531A MX 2012002531 A MX2012002531 A MX 2012002531A MX 2012002531 A MX2012002531 A MX 2012002531A
- Authority
- MX
- Mexico
- Prior art keywords
- broad
- generation
- cell response
- against hiv
- humans against
- Prior art date
Links
- 230000005867 T cell response Effects 0.000 title 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24964409P | 2009-10-08 | 2009-10-08 | |
| EP10001264 | 2010-02-08 | ||
| PCT/EP2010/006114 WO2011042180A1 (en) | 2009-10-08 | 2010-10-06 | Generation of a broad t-cell response in humans against hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002531A true MX2012002531A (es) | 2012-04-11 |
Family
ID=46396898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002531A MX2012002531A (es) | 2009-10-08 | 2010-10-06 | Generacion de una respuesta amplia de celulas t en humanos contra el virus de inmunodeficiencia humana (vih). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120135032A1 (enExample) |
| EP (1) | EP2486138A1 (enExample) |
| JP (1) | JP2013507107A (enExample) |
| KR (1) | KR20120093941A (enExample) |
| CN (1) | CN102656271A (enExample) |
| AU (1) | AU2010305030A1 (enExample) |
| CA (1) | CA2767924A1 (enExample) |
| EA (1) | EA201270108A1 (enExample) |
| MX (1) | MX2012002531A (enExample) |
| SG (1) | SG178909A1 (enExample) |
| WO (1) | WO2011042180A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| AU2014231229A1 (en) * | 2013-03-15 | 2015-09-17 | Bavarian Nordic A/S | Single high dose of MVA induces a protective immune response in neonates and infants |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| WO2017007994A1 (en) | 2015-07-08 | 2017-01-12 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| IL300730A (en) | 2016-07-08 | 2023-04-01 | American Gene Tech Int Inc | Pre-HIV vaccine and immunotherapy |
| US20220249653A1 (en) * | 2019-06-27 | 2022-08-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for detecting hiv latency, treating hiv infection, and reversing hiv latency |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| CA2392877C (en) * | 1999-12-23 | 2011-11-15 | Tomas Hanke | Improvements in or relating to immune responses to hiv |
| JP2004525604A (ja) * | 2000-07-14 | 2004-08-26 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | Ｈｉｖアクセサリータンパク質をコードするｄｎａワクチン |
| AU3163902A (en) | 2000-11-23 | 2002-06-03 | Bavarian Nordic Res Inst As | Modified vaccinia ankara virus variant |
| BR0214822A (pt) | 2001-12-10 | 2004-12-14 | Bavarian Nordic As | Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveis |
| PL372091A1 (pl) | 2002-05-16 | 2005-07-11 | Bavarian Nordic A/S | Ekspresja genów w zmodyfikowanym wirusie krowianki Ankara uzyskana w wyniku zastosowania promotora ATI wirusa ospy krów |
| EP1652857B9 (en) | 2002-05-16 | 2009-10-14 | Bavarian Nordic A/S | Fusion protein of HIV regulatory/accessory proteins |
| EA007811B1 (ru) | 2002-05-16 | 2007-02-27 | Бавариан Нордик А/С | Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva) |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| CA2597511A1 (en) | 2005-02-24 | 2006-11-23 | Medical Research Council | Hivcon: an hiv immunogen and uses thereof |
| ES2281252B1 (es) | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
| WO2008118936A2 (en) | 2007-03-26 | 2008-10-02 | International Aids Vaccine Initiative | Method of elicting immune response with a modified mva viral hiv-1 vector |
| US8268327B2 (en) * | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| WO2009056535A2 (en) * | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
-
2010
- 2010-10-06 SG SG2012013983A patent/SG178909A1/en unknown
- 2010-10-06 AU AU2010305030A patent/AU2010305030A1/en not_active Abandoned
- 2010-10-06 KR KR1020127011933A patent/KR20120093941A/ko not_active Withdrawn
- 2010-10-06 MX MX2012002531A patent/MX2012002531A/es not_active Application Discontinuation
- 2010-10-06 EA EA201270108A patent/EA201270108A1/ru unknown
- 2010-10-06 CN CN2010800415531A patent/CN102656271A/zh active Pending
- 2010-10-06 EP EP10765582A patent/EP2486138A1/en not_active Withdrawn
- 2010-10-06 JP JP2012532489A patent/JP2013507107A/ja not_active Withdrawn
- 2010-10-06 WO PCT/EP2010/006114 patent/WO2011042180A1/en not_active Ceased
- 2010-10-06 US US13/389,411 patent/US20120135032A1/en not_active Abandoned
- 2010-10-06 CA CA2767924A patent/CA2767924A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010305030A1 (en) | 2012-05-10 |
| JP2013507107A (ja) | 2013-03-04 |
| WO2011042180A1 (en) | 2011-04-14 |
| EP2486138A1 (en) | 2012-08-15 |
| EA201270108A1 (ru) | 2012-08-30 |
| SG178909A1 (en) | 2012-04-27 |
| CN102656271A (zh) | 2012-09-05 |
| KR20120093941A (ko) | 2012-08-23 |
| CA2767924A1 (en) | 2011-04-14 |
| US20120135032A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG178909A1 (en) | Generation of a broad t-cell response in humans against hiv | |
| JP2012509340A5 (enExample) | ||
| EP3967323A3 (en) | Hiv vaccine | |
| WO2008118849A3 (en) | Hiv-1 protease inhibitors | |
| WO2007144720A3 (en) | Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| NZ607477A (en) | Non-natural amino acid replication-dependent microorganisms and vaccines | |
| MX344879B (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| NZ602504A (en) | Antiviral vaccines with improved cellular immunogenicity | |
| JP2013507107A5 (enExample) | ||
| EA201290956A1 (ru) | Вакцина против вич | |
| NZ597458A (en) | Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means | |
| MX343505B (es) | Metodos y composiciones para inhibir la transmision del vih. | |
| MX2014014682A (es) | Glicoproteina 120 (gp120) estabilizada. | |
| WO2010041241A3 (en) | Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding | |
| MX2017009812A (es) | Composiciones y metodos para inhibir infeccion viral. | |
| WO2016086153A3 (en) | Use of hsp90 inhibitors for the treatment of hiv infections and aids | |
| MY187896A (en) | Dengue virus vaccine compositions and methods of use thereof | |
| WO2015086738A3 (en) | Hiv vaccine | |
| WO2015048796A3 (en) | Mosaic hiv envelope immunogenic polypeptides | |
| PH12012501930A1 (en) | Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer | |
| WO2016106107A3 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| MX354571B (es) | Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1). | |
| ATE486088T1 (de) | Hiv-impfstoff | |
| PH12020551944A1 (en) | Reverse peptide vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |